On Monday, shares of biotechnology company Structure Therapeutics (GPCR) surged nearly 103%, driven directly by positive mid-stage clinical trial data for its oral weight loss drug candidate. The company, which focuses on metabolic diseases, reported strong performance for its GLP-1 receptor agonist candidate, aleniglipron, in a 36-week Phase 2b clinical trial.
Study data showed that participants receiving aleniglipron achieved an average weight reduction of over 11% compared to the placebo group, with the effect appearing dose-dependent. Among those on higher doses, weight loss reached up to 15.3% relative to the placebo group. In terms of safety, approximately 10.4% of participants discontinued the trial due to adverse events, with overall tolerability largely consistent with existing GLP-1 class obesity treatments.
In a press release, CEO Raymond Stevens stated that aleniglipron offers differentiated advantages, delivering clinically meaningful and significant weight loss with a safety profile suitable for long-term treatment. Based on these positive results, Structure Therapeutics plans to advance the drug into Phase 3 clinical trials and expects to meet with the U.S. Food and Drug Administration in 2026 to discuss further development plans. This progress has drawn significant investor attention to Structure Therapeutics in the increasingly competitive weight loss drug market.
